title: [Estrogens and cardiovascular diseases: should current guidelines be changed?].
abstract: Survey about oral contraceptives and postmenopausal hormonal replacement therapy and the effects on coagulation system. The question to withdraw oral contraceptives 4 weeks before a gynecological operation cannot be answered sufficiently. The pros and cons have been discussed. Thromboembolic disorders in the history of a patient are contraindications for oral contraceptives. It can be anticipated, that this rule will be changed in future. There are no scientific hints, which could bring a phlebitis or varicosis in connection etiologically with a thromboembolic disorder during oral contraceptives.
authors.affiliation: Department of Obstetrics and Gynecology, Medical College, University of Iowa City.
authors.forename: F
authors.initials: F
authors.lastname: Beller
authors.forename: W
authors.initials: W
authors.lastname: Theiss
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control; D003276:Contraceptives, Oral / Q000008:administration & dosage / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000139:chemically induced* / Q000517:prevention & control; D013924:Thrombophlebitis / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D003276:Contraceptives, Oral
vernacular_title: Ostrogene und kardiovaskuläre Erkrankungen: Müssen die geltenden Richtlinien geändert werden?